Abeona Therapeutics Inc (NASDAQ:ABEO)’s share price fell 9.5% during mid-day trading on Friday . The company traded as low as $7.48 and last traded at $7.52. 543,459 shares were traded during trading, an increase of 35% from the average session volume of 403,457 shares. The stock had previously closed at $8.31.
A number of research firms have recently issued reports on ABEO. BidaskClub upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, February 21st. ValuEngine downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Thursday, December 6th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $26.00.
The stock has a market cap of $360.58 million, a P/E ratio of -6.32 and a beta of 1.93.
About Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also: Systematic Risk
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.